视索克隆
医学
强的松
神经母细胞瘤
肌阵挛
儿科
共济失调
内科学
精神科
遗传学
细胞培养
生物
作者
Brian H. Kushner,Yasmin Khakoo
标识
DOI:10.1016/s2352-4642(17)30129-3
摘要
Published in The Lancet Child & Adolescent Health, Pedro de Alarcon and colleagues 1 de Alarcon PA Matthay KK London WB et al. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child & Adol Health. 2017; (published online Nov 3)http://dx.doi.org/10.1016/S2352-4642(17)30130-X Google Scholar and the Children's Oncology Group (COG) merit plaudits for conducting the only prospective randomised therapeutic study of patients with neuroblastoma associated with opsoclonus myoclonus ataxia syndrome (OMA). 1 de Alarcon PA Matthay KK London WB et al. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child & Adol Health. 2017; (published online Nov 3)http://dx.doi.org/10.1016/S2352-4642(17)30130-X Google Scholar These are fascinating entities: neuroblastoma is renowned for having the widest range of clinical manifestations and natural history of any neoplasm, and OMA is notorious for the sudden onset, in a previously thriving toddler, of relentless jerking of limbs, rapid, irregular, and conjugate eye movements, and behavioural changes including rage attacks. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trialThe addition of IVIG to prednisone and risk-adapted chemotherapy improved OMA response, and this regimen constitutes a backbone on which to build additional therapy. Full-Text PDF Correction to Lancet Child Adolesc Health 2018; 2: 3–5Kushner B H. Enigmatic entities: opsoclonus myoclonus ataxia syndrome linked to neuroblastoma. Lancet Child Adolesc Health 2018; 2: 3–5. In this Comment, the list of authors has been corrected to include Yasmin Khakoo. This correction has been made to the online version as of March 13, 2018. Full-Text PDF
科研通智能强力驱动
Strongly Powered by AbleSci AI